Stroke
Conditions
Interventions
Experimental Group:Patients assumed a seated position with forearms hanging naturally. They performed shoulder flexion movements from 0 to 60 degrees under four distinct test conditions. The specific
2. Bilateral movement
3. Affected-side suspended movement
4. Bilateral suspended movement. All movements were required to be completed at a constant speed within 5 seconds, with only the middle 3 seconds of electromyographic signals collected for subsequent
Control Group:Only unilateral movement tasks were performed, with the same movement specifications, completion time limits, and data collection standards as the experimental group.
Sponsors
China-Japan Friendship Hospital
Eligibility
Sex/Gender
Male
Age
50 Years to 80 Years
Inclusion criteria
Inclusion criteria: Experimental Group: 1. Meets the relevant diagnostic criteria outlined in the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke (2023 Edition) and is definitively diagnosed via CT or MRI imaging; 2. Affected upper limb motor function is at Brunnstrom Stage III–IV, with active shoulder flexion range of motion reaching 0–60°; 3. Stroke duration is 3–12 months, within the subacute phase; 4. Aged 50–80 years; 5. Normal cognitive function with Montreal Cognitive Assessment (MoCA) score >=26, no hearing or visual impairment, and no history of psychiatric disorders; 6. Right-handed. Control Group: 1. Aged 50–80 years; 2. Right-handed; 3. Non-manual occupation; 4. No organic shoulder joint pathology and no shoulder pain-related symptoms; 5. Normal cognitive function with Montreal Cognitive Assessment (MoCA) score >=26, no history of organic neuropsychiatric disorders.
Exclusion criteria
Exclusion criteria: 1. Patients with combined dysfunction of vital organs such as the heart, liver, or kidneys; 2. Patients with unstable conditions at risk of new myocardial infarction or hemorrhage; 3. Patients with severe spasticity in the affected upper limb, scoring >2 on the Modified Ashworth Scale (MAS); 4. Patients with cognitive or behavioral impairments unable to cooperate with trial procedures and assessments; 5. Patients with other systemic diseases that may affect trial outcomes.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Activation level; | — |
Secondary
| Measure | Time frame |
|---|---|
| Activation sequence; | — |
Countries
China
Contacts
Public ContactRuidong Ge
China-Japan Friendship Hospital
Outcome results
None listed